The relationship between the gut microbiome and mild cognitive impairment in patients without dementia: a

Naoki Saji1, Kenta Murotani2, Takayoshi Hisada3

  • 1Center for Comprehensive Care and Research on Memory Disorders, National Center for Geriatrics and Gerontology, Aichi, Japan. sajink@nifty.com.

Scientific Reports
|December 20, 2019
PubMed

Insights

An increased prevalence of the gut bacterium Bacteroides is linked to mild cognitive impairment (MCI) in individuals without dementia. This finding suggests a potential gut microbiome marker for early cognitive decline.

Area of Science:

  • Microbiology
  • Neuroscience
  • Gerontology

Background:

  • Gut microbiome dysregulation is associated with dementia.
  • The link between gut microbiota and mild cognitive impairment (MCI) in non-demented individuals is not well understood.

Purpose of the Study:

  • To investigate the association between the gut microbiome composition and MCI in patients without dementia.
  • To identify potential gut microbiome biomarkers for early cognitive decline.

Main Methods:

  • Cross-sectional analysis of 82 patients (61 with MCI).
  • Gut microbiome assessment using terminal restriction fragment length polymorphism (T-RFLP).
  • Multivariable logistic regression and graphical modeling to identify associations.

Main Results:

  • Patients with MCI showed a higher prevalence of Bacteroides compared to controls.
  • Increased Bacteroides abundance correlated with white matter hyperintensity and higher VSRAD scores (indicating atrophy).
  • Multivariable analysis confirmed Bacteroides prevalence as an independent factor associated with MCI.

Conclusions:

  • Elevated levels of Bacteroides are independently associated with the presence of MCI in individuals without dementia.
  • Gut microbiome alterations, specifically increased Bacteroides, may serve as an early indicator of cognitive impairment.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
463
Assessment of the Gastrointestinal System II: Health Perception Pattern01:29

Assessment of the Gastrointestinal System II: Health Perception Pattern

Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health Perception Patterns
Health perception patterns offer valuable insights into a patient's lifestyle habits and how they may impact their GI health. These patterns include:
411
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
709
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
682